Goodwin Procter advised Bicara Therapeutics on the deal.Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program BCA101…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now